Yale epidemiology professor Dr. Harvey Risch told Fox News's "Ingraham Angle" that he thinks hydroxychloroquine could save 75,000 to 100,000 lives if widely used to treat COVID-19, and that it's unfortunate that a "propaganda war" has been waged on the commonly prescribed drug which is not based on "medical facts."
"There are many doctors that I’ve gotten hostile remarks about saying that all the evidence is bad for it and, in fact, that is not true at all," Risch said on Monday, adding that he believes the drug should be used as a prophylactic for front-line healthcare workers, as has been done in India.
Researchers at the Henry Ford Health System in Southeast Michigan have found that early administration of hydroxychloroquine makes hospitalized patients substantially less likely to die.
The study, published in the International Journal of Infectious Diseases, determined that hydroxychloroquine provided a "66 percent hazard ratio reduction," and hydroxychloroquine and azithromycin a 71 percent reduction, compared with neither treatment.
In-hospital mortality was 18.1 percent overall; 13.5 percent with just hydroxychloroquine, 22.4 percent with azithromycin alone, and 26.4 percent with neither drug. "Prospective trials are needed" for further review, the researchers note, even as they concluded: "In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality." -Fox News
"All the evidence is actually good for it when it is used in outpatient uses. Nevertheless, the only people who actually say that are a whole pile of doctors who are on the front lines treating those patients across the country and they are the ones who are at risk being forced not to do it," Risch added, arguing that the MSM refuses to cover the benefits of the drug, and is actively silencing those trying to address the efficacy of HCQ.
Imagine how many people have died thanks to the media's 'propaganda war.'
"Our results do differ from some other studies," said Dr. Marcus Zervos, head of the Henry Ford Health System's infectious diseases unit. "What we think was important in ours ... is that patients were treated early. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with COVID."